Novel Oncogenic PDGFRB Variant in Severe Infantile Myofibromatosis With Response to Imatinib Using Therapeutic Drug Monitoring

JCO Precis Oncol. 2022 Oct:6:e2200250. doi: 10.1200/PO.22.00250.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Carcinogenesis
  • Drug Monitoring
  • Humans
  • Imatinib Mesylate / therapeutic use
  • Myofibromatosis* / congenital
  • Myofibromatosis* / drug therapy
  • Receptor, Platelet-Derived Growth Factor beta / genetics

Substances

  • Imatinib Mesylate
  • PDGFRB protein, human
  • Receptor, Platelet-Derived Growth Factor beta

Supplementary concepts

  • Fibromatosis, Congenital Generalized